{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:00:46Z","timestamp":1762408846053},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ijantimicag.2012.01.012","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T11:02:50Z","timestamp":1332500570000},"page":"376-380","source":"Crossref","is-referenced-by-count":53,"title":["Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections"],"prefix":"10.1016","volume":"39","author":[{"given":"Leonard","family":"Amaral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Viveiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0005","unstructured":"Dreaper J. TB: plan to tackle rise in drug-resistant cases. BBC Mobile News Health 13 September 2011."},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cid\/cir889","article-title":"Totally drug-resistant tuberculosis in India","volume":"54","author":"Udwadia","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0015","article-title":"Resolving the public health crisis in the developing world: problems and barriers of access to essential medicines","volume":"5","author":"Mercurio","year":"2007","journal-title":"Northwestern Univ J Int Hum Rights"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0020","first-page":"1012","article-title":"Costs of patients hospitalized for multidrug-resistant tuberculosis","volume":"8","author":"Rajbhandary","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0025","series-title":"British National Formulary, No. 60","first-page":"214","year":"2010"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0924-8579(99)00153-3","article-title":"Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies","volume":"14","author":"Amaral","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/47.5.505","article-title":"Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy","volume":"47","author":"Amaral","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jac\/40.3.319","article-title":"The potential management of resistant infections with non-antibiotics","volume":"40","author":"Kristiansen","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0045","first-page":"521","article-title":"Studies on antituberculotic action of some phenothiazine derivatives in vitro","volume":"239","author":"Moln\u00e1r","year":"1977","journal-title":"Zentralbl Bakteriol Orig A"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0050","first-page":"393","article-title":"The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria","volume":"94","author":"Kristiansen","year":"1986","journal-title":"Acta Pathol Microbiol Immunol Scand B"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0055","first-page":"1","article-title":"Creation of a tuberculosis directly observed therapy provider network in New York City: a new model of public health","volume":"1","author":"Klein","year":"1995","journal-title":"J Public Health Manag Pract"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0060","first-page":"725","article-title":"Antimicrobial activity of phenothiazines","volume":"18","author":"Amaral","year":"2004","journal-title":"In Vivo"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0065","first-page":"733","article-title":"The in vitro activity of phenothiazines against Mycobacterium avium: potential of thioridazine for therapy of the co-infected AIDS patient","volume":"19","author":"Viveiros","year":"2005","journal-title":"In Vivo"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/187152607782110022","article-title":"Phenothiazines as anti-multi-drug resistant tubercular agents","volume":"7","author":"Amaral","year":"2007","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0075","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000239036","article-title":"a drug potentially useful for treating mycobacterial infections","volume":"38","author":"Crowle","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0080","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0924-977X(99)00034-6","article-title":"Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants","volume":"9","author":"Daniel","year":"1999","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jac\/38.6.1049","article-title":"Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis","volume":"38","author":"Amaral","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0924-8579(00)00199-0","article-title":"Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis","volume":"16","author":"Bettencourt","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0095","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.47.3.917-922.2003","article-title":"Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis","volume":"47","author":"Ordway","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/17460913.3.2.135","article-title":"The TB laboratory of the future: macrophage-based selection of XDR-TB therapeutics","volume":"3","author":"Martins","year":"2008","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0105","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2174\/138945008785747798","article-title":"Promising therapy of XDR-TB\/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps","volume":"9","author":"Amaral","year":"2008","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijantimicag.2008.10.028","article-title":"SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB)","volume":"33","author":"Martins","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijantimicag.2006.10.013","article-title":"In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis","volume":"29","author":"Martins","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0120","first-page":"771","article-title":"The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis","volume":"21","author":"Martins","year":"2007","journal-title":"In Vivo"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012640","article-title":"The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis","volume":"5","author":"van Soolingen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/157489111796064542","article-title":"Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of \u201cnew uses\u201d","volume":"6","author":"Amaral","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0135","first-page":"19","article-title":"Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacables epidemiol\u00f3gicos, bacteriol\u00f3gicos, terap\u00e9uticos y evolutivos","volume":"1","author":"Abbate","year":"2007","journal-title":"Revista Argentina de Medicina Respiratoria"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkr500","article-title":"Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine","volume":"67","author":"Abbate","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157489111796064614","article-title":"Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB","volume":"6","author":"Udwadia","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ijantimicag.2009.12.019","article-title":"Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now","volume":"35","author":"Amaral","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijantimicag.2011.01.010","article-title":"Role of calcium in the efflux system of Escherichia coli","volume":"37","author":"Martins","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0160","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1986.4.6.994","article-title":"Calmodulin: a potential target for cancer chemotherapeutic agents","volume":"4","author":"Hait","year":"1986","journal-title":"J Clin Oncol"},{"issue":"Suppl. 8","key":"10.1016\/j.ijantimicag.2012.01.012_bib0165","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/00005344-198600088-00011","article-title":"Different modes of interaction of calmodulin with its target enzymes","volume":"8","author":"Klee","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2265.1985.tb00216.x","article-title":"Calcium calmodulin and hormone secretion","volume":"23","author":"Brown","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0175","first-page":"2138","article-title":"Overview on the research on calmodulin and its inhibitors","volume":"41","author":"Hidaka","year":"1983","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0180","first-page":"1","article-title":"Calmodulin: its role in calcium-mediated cellular regulation","volume":"8","author":"Oldham","year":"1982","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clim.2004.07.016","article-title":"Mechanisms of mycobacterial persistence in tuberculosis","volume":"114","author":"Kusner","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1474-9728.2004.00100.x","article-title":"Signalling shutdown strategies in aging immune cells","volume":"3","author":"Ayub","year":"2004","journal-title":"Aging Cell"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0195","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1369-5274(98)80066-0","article-title":"Signaling and host cell invasion by Trypanosoma cruzi","volume":"1","author":"Burleigh","year":"1998","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10937409809524547","article-title":"The alveolar macrophage as a model of calcium signaling in oxidative stress","volume":"1","author":"Hoyal","year":"1998","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0205","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11427-011-4203-9","article-title":"Distinctive characteristics and functions of multiple mitochondrial Ca2+ influx mechanisms","volume":"54","author":"Pan","year":"2011","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0210","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/978-1-4419-9533-9_5","article-title":"Regulators of Ca2+ signaling in mast cells: potential targets for treatment of mast cell-related diseases?","volume":"716","author":"Ma","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0215","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1042\/BST0390789","article-title":"A diversity of SERCA Ca2+ pump inhibitors","volume":"39","author":"Michelangeli","year":"2011","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0220","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00467-011-1816-y","article-title":"Calcium signaling triggered by ouabain protects the embryonic kidney from adverse developmental programming","volume":"26","author":"Khodus","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0225","first-page":"726","article-title":"The diversity of mechanisms of the ion channels blockade as a way towards designing new pharmacological agents","volume":"96","author":"Tikhonov","year":"2010","journal-title":"Ross Fiziol Zh Im I M Sechenova"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0230","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-60761-500-2_9","article-title":"Store-operated calcium entry channels in pulmonary endothelium: the emerging story of TRPCS and Orai1","volume":"661","author":"Cioffi","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0235","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1515\/znc-2009-5-625","article-title":"Inhibitors of ABC transporters and biophysical methods to study their activity","volume":"64","author":"Bartosiewicz","year":"2009","journal-title":"Z Naturforsch C"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0240","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/cmdc.200800452","article-title":"Small-molecule inhibitors of store-operated calcium entry","volume":"4","author":"Sweeney","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0245","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ymeth.2008.09.009","article-title":"Methods for studying store-operated calcium entry","volume":"46","author":"Bird","year":"2008","journal-title":"Methods"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0250","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1073\/pnas.83.2.451","article-title":"Potassium channels mediate killing by human natural killer cells","volume":"83","author":"Schlichter","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0255","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nature02356","article-title":"The large-conductance Ca2+-activated K+ channel is essential for innate immunity","volume":"427","author":"Ahluwalia","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/416291a","article-title":"Killing activity of neutrophils is mediated through activation of proteases by K+ flux","volume":"416","author":"Reeves","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0265","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/157489111796064524","article-title":"Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)\u2014a novel, patentable approach to limit the emergence of XDR-TB","volume":"6","author":"Martins","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0270","first-page":"69","article-title":"Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages","volume":"22","author":"Martins","year":"2008","journal-title":"In Vivo"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0275","first-page":"409","article-title":"Phenothiazines, bacterial efflux pumps and targeting the macrophage for enhanced killing of intracellular XDRTB","volume":"24","author":"Amaral","year":"2010","journal-title":"In Vivo"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0280","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/9780470920541.ch3","article-title":"Efflux pumps of the resistance\u2013nodulation\u2013division family: a perspective of their structure, function, and regulation in Gram-negative bacteria","volume":"77","author":"Routh","year":"2011","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0285","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/9780470920541.ch2","article-title":"Efflux pumps of Gram-negative bacteria: genetic responses to stress and the modulation of their activity by pH, inhibitors, and phenothiazines","volume":"77","author":"Amaral","year":"2011","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0290","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.2174\/092986711796150469","article-title":"An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat Gram-negative resistant bacteria","volume":"18","author":"Pag\u00e8s","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0295","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.mib.2009.07.003","article-title":"Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update","volume":"12","author":"Blair","year":"2009","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0300","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.19.2.382-402.2006","article-title":"Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria","volume":"19","author":"Piddock","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0305","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/07853890701195262","article-title":"Efflux pumps as antimicrobial resistance mechanisms","volume":"39","author":"Poole","year":"2007","journal-title":"Ann Med"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-695X.2011.00831.x","article-title":"Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis","volume":"63","author":"da Silva","year":"2011","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0315","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2165\/11317030-000000000-00000","article-title":"Efflux-mediated drug resistance in bacteria: an update","volume":"69","author":"Li","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0320","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0924-8579(03)00208-5","article-title":"Mycobacterial efflux pumps and chemotherapeutic implications","volume":"22","author":"Viveiros","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2011.08.009","article-title":"Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex","author":"Rodrigues","year":"2011","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0330","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/157489111796064579","article-title":"Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors","volume":"6","author":"Rodrigues","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0335","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2180-11-35","article-title":"Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance","volume":"11","author":"Rodrigues","year":"2011","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0340","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijantimicag.2009.07.010","article-title":"The role of efflux pumps in macrolide resistance in Mycobacterium avium complex","volume":"34","author":"Rodrigues","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0345","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijantimicag.2010.10.014","article-title":"Confronting multidrug-resistant Acinetobacter baumannii: a review","volume":"37","author":"Neonakis","year":"2011","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2012.01.012_bib0350","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.ijantimicag.2010.11.014","article-title":"Multidrug-resistant Gram-negative bacteria: how to treat and for how long","volume":"36","author":"Giamarellou","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0355","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1051\/medsci\/20102611960","article-title":"Multi-drug resistant Pseudomonas aeruginosa: towards a therapeutic dead end?","volume":"26","author":"Barbier","year":"2010","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0360","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/157488410791110797","article-title":"Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis","volume":"5","author":"Dartois","year":"2010","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0365","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2165\/11315690-000000000-00000","article-title":"Multidrug-resistant Gram-negative infections: what are the treatment options?","volume":"69","author":"Giamarellou","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0370","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/AAC.46.9.2804-2810.2002","article-title":"Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis","volume":"46","author":"Viveiros","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0375","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1164\/rccm.201011-1924OC","article-title":"Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux","volume":"184","author":"Louw","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0380","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/157489111796064597","article-title":"New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: a gene regulation perspective","volume":"6","author":"Dutta","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0405","doi-asserted-by":"crossref","unstructured":"Machado D, Couto I, Perdig\u00e3o J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, Viveiros M., 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis, in press.","DOI":"10.1371\/journal.pone.0034538"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0385","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.bbapap.2008.12.011","article-title":"Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria","volume":"1794","author":"Pag\u00e8s","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0390","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2174\/138945008785747815","article-title":"Control and regulation of permeability of MDR bacterial pathogens to antibiotics presented by COST Action BM0701","volume":"9","author":"Amaral","year":"2008","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0395","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ijantimicag.2009.06.029","article-title":"An AcrAB-mediated multidrug-resistant phenotype is maintained following restoration of wild-type activities by efflux pump genes and their regulators","volume":"34","author":"Martins","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.01.012_bib0400","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/157489111796064551","article-title":"Latent tuberculosis: is there a role for thioridazine?","volume":"6","author":"Sohaskey","year":"2011","journal-title":"Recent Pat Antiinfect Drug Discov"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857912000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857912000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T20:47:37Z","timestamp":1561495657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857912000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0924857912000532"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.01.012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}